Last $357.53 USD
Change Today +3.88 / 1.10%
Volume 1.1M
BIIB On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 8:10 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

biogen idec inc (BIIB) Snapshot

Open
$352.98
Previous Close
$353.65
Day High
$359.87
Day Low
$352.03
52 Week High
01/21/15 - $366.17
52 Week Low
04/15/14 - $272.02
Market Cap
84.4B
Average Volume 10 Days
1.9M
EPS TTM
$10.34
Shares Outstanding
236.2M
EX-Date
--
P/E TM
34.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOGEN IDEC INC (BIIB)

biogen idec inc (BIIB) Details

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. It provides AVONEX to treat relapsing MS; TYSABRI to treat relapsing forms of MS and Crohn’s disease; RITUXAN for treating relapsed or refractory, follicular, CD20-positive, and B-cell Non-Hodgkin’s lymphoma (NHL); FUMADERM to treat severe plaque psoriasis in adult patients; FAMPYRA, an oral compound for the improvement of walking in adult patients with MS; TECFIDERA for the treatment of MS; and GAZYVA, an injection for intravenous infusion that treats an untreated chronic lymphocytic leukemia. The company’s products that completed Phase III clinical trials comprise ELOCTATE and ALPROLIX, an inherited disorder that inhibits blood coagulations; and Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company’s Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; Neublastin for neuropathic pain; and ANTI-TWAEK for lupus nephritis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; BIIB037 for MS; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial products include ISIS-SMNRx for spinal muscular atrophy. Biogen Idec Inc. has collaboration agreements with Genentech, Inc.; Acorda Therapeutics, Inc.; Sangamo BioSciences; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.

6,850 Employees
Last Reported Date: 02/6/14
Founded in 1985

biogen idec inc (BIIB) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $745.2K
Executive Vice President of Global Commercial...
Total Annual Compensation: $675.1K
Executive Vice President of Research & Develo...
Total Annual Compensation: $766.8K
Executive Vice President of Pharmaceutical Op...
Total Annual Compensation: $625.6K
Compensation as of Fiscal Year 2013.

biogen idec inc (BIIB) Key Developments

Biogen Idec Inc. Mulls Acquisitions

Biogen Idec Inc. (NasdaqGS:BIIB) is seeking acquisitions. Unidentified Company Representative of Biogen Idec Inc. in a JPMorgan Healthcare Conference said “So we're pretty excited about the target and the molecule, and I think that's the flavor of transactions as Paul calls them tuck-in acquisitions that you will continue to see us do.”

Biogen Idec Inc. and Columbia University Medical Center to Conduct Collaborative Genetics Research

Biogen Idec Inc. and Columbia University Medical Center have formed a $30 million strategic alliance to conduct genetics discovery research on the underlying causes of disease and to identify new treatment approaches. The agreement will integrate genomics research conducted at Columbia with Biogen Idec’s understanding of disease mechanisms and pathways, and expertise in discovering new medicines. The collaboration will enable Biogen Idec and Columbia to investigate the genomes of patients showing unusual treatment responses or unique disease presentations and to explore the connections among genes, pathways, and disease processes. The ultimate goal will be to provide multiple qualified targets for new therapeutic approaches, increasing the potential for the development of new treatments.

Biogen Idec Reports Positive Top-Line Results from Phase 2 Anti-LINGO-1 Trial in People with Acute Optic Neuritis

Biogen Idec announced top-line results from the Phase 2 acute optic neuritis (AON) RENEW trial in which treatment with anti-LINGO-1 showed evidence of biological repair of the visual system. Anti-LINGO-1 demonstrated an improvement in the study's primary endpoint, recovery of optic nerve latency (time for a signal to travel from the retina to the visual cortex), as measured by full field visual evoked potential (FF-VEP), relative to placebo. The study showed no effect on secondary endpoints, including change in thickness of the retinal layers (optic nerve neurons and axons) and visual function, as measured by spectral domain optical coherence tomography (SD-OCT) and low contrast letter acuity, respectively. AON damages the optic nerve, causing loss of the myelin sheath and axonal injury, and may result in loss of visual function. AON is considered a good clinical model to measure the hypothesized mechanisms of action of anti-LINGO-1, remyelination and neuroprotection. RENEW was designed to study anti-LINGO-1's ability to enable repair of an optic nerve lesion via axonal remyelination following the onset of a first episode of AON. RENEW is part of the anti-LINGO-1 Phase 2 clinical development program, which includes the SYNERGY trial in multiple sclerosis. RENEW studied the effects on remyelination by measuring the latency of nerve conduction between the retina and the visual cortex in the brain using FF-VEP. The primary endpoint measured FF-VEP latency for the affected eye at week 24 compared to the unaffected fellow eye at baseline. Results demonstrated a 34% improvement (p=0.0504) in the recovery of optic nerve latency compared to placebo in the per-protocol population. The analysis of the intent-to-treat (ITT) population, which includes patients in both arms who did not complete the study, showed a positive trend but did not reach statistical significance. Anti-LINGO-1 was generally well tolerated. The overall incidence and severity of adverse events (AEs) was comparable across treatment arms. Treatment-related anti-LINGO-1 serious adverse events (SAEs) consisted of two patients with hypersensitivity reactions occurring around the time of infusion and one patient with an asymptomatic elevation in liver transaminases which resolved after drug discontinuation. No deaths occurred during the trial. No immunogenicity was observed.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIIB:US $357.53 USD +3.88

BIIB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,767 JPY -17.00
Bristol-Myers Squibb Co $62.07 USD -0.02
Celgene Corp $123.89 USD +0.18
Novo Nordisk A/S kr299.30 DKK +6.30
Shire PLC 4,923 GBp +107.00
View Industry Companies
 

Industry Analysis

BIIB

Industry Average

Valuation BIIB Industry Range
Price/Earnings 33.9x
Price/Sales 9.4x
Price/Book 8.1x
Price/Cash Flow 28.6x
TEV/Sales 9.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGEN IDEC INC, please visit www.biogenidec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.